Scleral buckling has been successful method of treating rhegmatogenous retinal detachment for 70 years now. In the world of ubiquitous pars plana vitrectomy what has changed was indications and selection of patients for whom scleral buckling is still the first choice procedure. It seems that in young age patients cases scleral buckling should be considered in retinal detachment with holes located in adjacent quadrants and post traumatic retinal dialysis particularly.
PL
Zewnątrztwardówkowe operacje z zastosowaniem wszczepów nadtwardówkowych już od 70 lat stanowią skuteczną metodę leczenia otworopochodnych odwarstwień siatkówki. Obecnie, w dobie powszechnej witrektomii, zmieniły się jednak wskazania i populacja pacjentów, u których pozostają one metodą pierwszego wyboru. Wydaje się, że u młodych osób każdorazowo powinno się rozważyć operację z użyciem wszczepu nadtwardówkowego, zwłaszcza w przypadkach odwarstwień siatkówki z otworami położonymi blisko siebie oraz pourazowego oderwania siatkówki od rąbka.
2
Dostęp do pełnego tekstu na zewnętrznej witrynie WWW
Retinal vein occlusion (RVO) and the resulting complications of diabetic maculopathy are the next most common vascular cause of impaired vision in the world. Management of RVO include identification and treatment of risk factors, diagnosis and treatment of vision impairment threatening complications. An important role in the treatment of macular edema in RVO play injections of anti-VEGF.
PL
Zakrzep żyły siatkówki (RVO, retinal vein occlusion) i wynikające z niego powikłania stanowią obok makulopatii cukrzycowej najczęstszą naczyniową przyczynę upośledzenia widzenia na świecie. Postępowanie w RVO obejmuje identyfikację i leczenie czynników ryzyka oraz rozpoznanie i leczenie zagrażających upośledzeniu wzroku powikłań. Istotną rolę w leczeniu obrzęku plamki w RVO odgrywają iniekcje anty-VEGF. Fotokoagulacja może być skuteczna jedynie w leczeniu zakrzepu gałęzi żyły środkowej siatkówki.
Flavonoids, polyphenolic compounds present in many food products, affect growth of different bacterial species when tested as purified or synthetic substances. They can also influence gene expression in human cells, like fibroblasts. Here, we asked if soy isoflavone extracts, commonly used in many products sold as anti-menopausal dietary supplements, influence bacterial growth similarly to a synthetic isoflavone, genistein. Four commercially available products were tested in amounts corresponding to genistein concentrations causing inhibition of growth of Vibrio harveyi (a model bacterium sensitive to this isoflavone) and Escherichia coli (a model bacterium resistant to genistein). Differential effects of various extracts on V. harveyi and E. coli growth, from stimulation, to no changes, to inhibition, were observed. Moreover, contrary to genistein, the tested extracts caused a decrease (to different extent) in viability of human dermal fibroblasts. These results indicate that effects of various soy isoflavone extracts on bacterial growth and viability of human cells are different, despite similar declared composition of the commercially available products.
Objectives. Recent epidemiological studies suggested an association between a poor vitamin D [25(OH)D] status, inflammatory mediators, and rheumatoid arthritis (RA). We have recently proposed that pro-inflammatory interleukin 6 (IL-6) may represent a good marker for disease activity of RA. The aim of this study was to investigate the relationship between serum 25(OH)D levels and disease activity, joint damage, as well as serum IL-6 levels in a Polish RA population. Materials and Methods. Serum 25(OH)D levels were measured in 35 female RA patients and 38 age- and gender-matched healthy controls. Statistical correlations between 25(OH)D levels and the disease activity score 28 (DAS 28), joint damage based on the Steinbrocker criteria, as well as serum IL-6 levels were performed. Results. There was no statistically significant difference between levels of 25(OH)D in RA (16.89±8.57 ng/ml) and healthy controls (14.12±7.51 ng/ml), and the vitamin D deficiency (<20 ng/ml) was found in 71.43% of RA patients and 73.68 % of healthy controls. While vitamin D status did not correlate with DAS 28 (r=0.265, p=0.149) and joint damage based on the Steinbrocker criteria (r=0.367, p=0.065), a positive correlation between 25(OH)D and IL-6 (r=0.537, p=0.002) was observed in RA. Conclusion. Although further studies on a larger group of patients will be needed to confirm the data presented here, it seems that hypovitaminosis D is common in the RA patients and middle-aged non-RA healthy women in the Polish population. 25(OH)D levels were similar in the RA patients and age- and gender-matched healthy controls, and were not associated with joint damage and disease activity in patients.
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.